KLF4公司
癌症研究
体内
髓样
克鲁佩尔
CD33
细胞分化
分化疗法
急性早幼粒细胞白血病
免疫学
医学
生物
细胞培养
川地34
转录因子
干细胞
细胞生物学
维甲酸
遗传学
基因
SOX2
作者
Mina Noura,Ken Morita,Hiroki Kiyose,Yukiko Okuno,Hidemasa Matsuo,Akihiro Koyama,Yoko Nishinaka‐Arai,Yasuhiko Kamikubo,Souichi Adachi
摘要
Differentiation therapy is a less toxic but still a very effective treatment for a subset of acute myeloid leukaemia (AML) cases. With the goal to identify novel compounds that can effectively and safely induce the terminal differentiation of non-acute promyelocytic leukaemia (APL) AML cells, we performed a chemical screening and identified albendazole (ABZ), a widely used anti-helminthic drug, as a promising lead compound that can differentiate non-APL AML cells by stimulating the Krüppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) differentiation axis to the monocytes. Our in vitro and in vivo findings demonstrate that ABZ is an attractive candidate drug as a novel differentiation chemotherapy for patients with non-APL AML.
科研通智能强力驱动
Strongly Powered by AbleSci AI